Predictive value of circulating fibroblast growth factor-23 and Klotho on protein-energy wasting in patients undergoing hemodialysis

被引:0
|
作者
Zhou, Xiaoling [1 ]
Luo, Yang [1 ]
Guo, Yidan [1 ]
Jia, Meng [1 ]
Zhang, Chunxia [1 ]
Shi, Zhihua [1 ]
Du, Ye [2 ,3 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Nephrol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China
[3] Beijing TB & Tumor Res Inst, Beijing, Peoples R China
来源
FRONTIERS IN NUTRITION | 2025年 / 11卷
关键词
hemodialysis; protein-energy wasting; fibroblast growth factor-23; Klotho; malnutrition; CHRONIC KIDNEY-DISEASE; INTERNATIONAL SOCIETY; RENAL NUTRITION; BONE; INFLAMMATION; MASS;
D O I
10.3389/fnut.2024.1497869
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: As a state of metabolic and nutritional derangements, protein-energy wasting (PEW) is highly prevalent and associated with increased morbidity and mortality in hemodialysis patients. Fibroblast growth factor-23 (FGF-23) and Klotho have been proven to contribute to chronic kidney disease-mineral and bone disorder (CKD-MBD) in patients undergoing hemodialysis. Previous evidence suggested that FGF-23 and Klotho may also contribute to the malnutritional status among these patients; however, the inter-relationship between the FGF-23-Klotho axis and PEW remains unclear. Therefore, we conducted this cross-sectional study to evaluate the association between plasma FGF-23 and Klotho levels and PEW in hemodialysis patients and to explore whether these markers could predict the presence of PEW. Methods: Plasma concentrations of FGF-23 and Klotho were measured, and their associations with PEW were assessed. PEW was evaluated based on body weight, muscle mass, biochemical data, and protein and energy intake, according to the 2008 criteria from the International Society of Renal Nutrition and Metabolism (ISRNM). Results: In this study, 147 hemodialysis patients (mean age 61.05 +/- 13.32 years) were enrolled, of whom 66 (44.90%) had PEW. PEW was significant positively correlated with FGF-23 (r = 0.403, p < 0.001), age (r = 0.225, p = 0.006), C-reactive protein (r = 0.236, p = 0.004), intact parathyroid hormone (r = 0.237, p = 0.004), and single-pool Kt/V (r = 0.170, p = 0.040), while it was negatively correlated with Klotho (r = -0.361, p < 0.001), hemoglobin (r = -0.215, p = 0.009), and serum creatinine (r = -0.278, p = 0.001). Logistic regression analyses showed that plasma FGF-23 and Klotho were independently associated with PEW, even after adjusting for covariables. The area under the ROC curve (AUC) of FGF-23 and Klotho in predicting PEW was 0.734 and 0.710 (p < 0.001), respectively. When the combination of FGF-23 and Klotho was used to predict PEW, its sensitivity was 81.8%, specificity was 60.5%, and the AUC was 0.746. Conclusion: Plasma levels of FGF-23 and Klotho are associated with PEW in hemodialysis patients. Higher plasma FGF-23 levels and lower Klotho levels may serve as valuable predictors of PEW in these patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Phosphate wasting and fibroblast growth factor-23
    Nanes, Mark S.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2013, 20 (06) : 523 - 531
  • [2] Regulation of fibroblast growth factor-23 signaling by Klotho
    Kurosu, H
    Ogawa, Y
    Miyoshi, M
    Yamamoto, M
    Nandi, A
    Rosenblatt, KP
    Baum, MG
    Schiavi, S
    Hu, CM
    Moe, OW
    Kuro-o, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) : 6120 - 6123
  • [3] Impact of sevelamer hydrochloride on fibroblast growth factor-23 levels in patients undergoing hemodialysis
    Ahmed, Fatma Abdelrahman
    Khalil, Amr
    Elsaid, Tamer
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2548 - I2548
  • [4] Impact of sevelamer hydrochloride on fibroblast growth factor-23 levels in patients undergoing hemodialysis
    Ahmed, Fatma Abdelrahman
    Khalil, Amr
    Elsaid, Tamer
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [5] Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients
    Esra Terzi Demirsoy
    Ozgür Mehtap
    Elif Birtas Atesoglu
    Pinar Tarkun
    Ayfer Gedük
    Necmi Eren
    Abdullah Hacihanefioglu
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 454 - 463
  • [6] Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients
    Demirsoy, Esra Terzi
    Mehtap, Ozgur
    Atesoglu, Elif Birtas
    Tarkun, Pinar
    Geduk, Ayfer
    Eren, Necmi
    Hacihanefioglu, Abdullah
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (03) : 454 - 463
  • [7] Predictive value of circulating fibroblast growth factor-23 on atrial fibrillation: A meta-analysis
    Meng, Lei
    Yang, Yajuan
    Zhang, Zhiwei
    Li, Guangping
    Liu, Tong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 210 : 68 - 71
  • [8] Fibroblast growth factor 21 and protein energy wasting in hemodialysis patients
    Post, Adrian
    Groothof, Dion
    Schutten, Joelle C.
    Kelly, Dylan
    Swarte, J. Casper
    Flores-Guerrero, Jose L.
    van der Veen, Yvonne
    Kema, Ido P.
    Ozyilmaz, Akin
    Enya, Ayano
    Westerhuis, Ralf
    Bakker, Stephan J. L.
    Franssen, Casper F. M.
    CLINICAL NUTRITION, 2021, 40 (06) : 4216 - 4224
  • [9] Fibroblast Growth Factor-23 importance as a prognostic factor in hemodialysis patients
    Al Atbee, Mohammed Younus Naji
    Hamu, Ali Hussein
    Hammoudi, Faten Abdulghani
    Allawi, Ali Abdulmajid Dyab
    Tuama, Hala Sami
    REVISTA LATINOAMERICANA DE HIPERTENSION, 2023, 18 (09): : 423 - 431
  • [10] Fibroblast growth factor-23 and Klotho in chronic kidney disease
    Vervloet, Marc G.
    Larsson, Tobias E.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2011, 1 (04) : 130 - 135